Investigation of the SLC22A23 gene in laryngeal squamous cell carcinoma

Ekizoglu, Seda; Seven, Didem; Ulutin, Turgut; Guliyev, Jalal; Buyru, Nur

doi:10.1186/s12885-018-4381-y

Cited by 13 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of the identified DESLCs, such as SLC39A4, RHBG, FLVCR1, SLC16A3, SLC22A1, SLC12A1, SLC29A2 and SLCO1B3 had been reported to play significant roles in HCC tumorigenesis (35)(36)(37)(38)(39)(40)(41)(42). Other DESLCs, such as XPR1, SLC22A23 and SLC2A5, were reported to be related to the other types of cancer (43)(44)(45). Interestingly, quite a few candidate DESLCs, such as SLC45A4, SLC26A9 and SLC26A6, remain uncharacterized in tumorigenesis.…”

Section: Discussionmentioning

confidence: 99%

Systemic characterization of the SLC family genes reveals SLC26A6 as a novel oncogene in hepatocellular carcinoma

Cao¹,

Wang²,

Chen³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Solute carrier (SLC) transporters play important roles in various physiological and pathological processes, such as cellular uptake of nutrients, cellular metabolism, tumor initiation and chemotherapy resistance. However, little is known about the comprehensive expression profile of SLC genes in human cancers, especially in human hepatocellular carcinoma (HCC).Methods: Comprehensive analysis was performed using the TCGA dataset to evaluate the expression profile and clinical significance of SLC family genes in HCC. Real-time PCR and immunohistochemistry (IHC) assays were conducted to validate the expression of solute carrier family 26 member 6 (SLC26A6) in clinical HCC tissues. Cell Counting Kit-8 (CCK8), colony formation and subcutaneous xenograft tumorigenesis assays were carried out to explore the functional role of SLC26A6 in HCC. Bioinformatic analyses were used to predict the potential molecular mechanism of SLC26A6 in HCC.Results: We identified 118 differentially expressed SLC genes (DESLCs) and found that there was a preferential enrichment for activated DESLCs in HCC. Clinical-relevant DESLCs identified a poor prognostic HCC subtype exhibiting unique clinicopathological and genomic profiles. SLC26A6 was overexpressed in HCC tissues both in mRNA and protein levels. Knockdown of SLC26A6 suppressed HCC tumorigenesis both in vitro and in vivo, indicating it as a promising therapeutic target. Finally, multifaceted bioinformatic analyses indicated that SLC26A6 might associate with multiple cancer-related pathways.Conclusions: This study highlights the potential roles of SLC genes in HCC tumorigenesis, and suggested SLC26A6 as a promising therapeutic target in HCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic characterization of the SLC family genes reveals SLC26A6 as a novel oncogene in hepatocellular carcinoma

Cao¹,

Wang²,

Chen³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…The global incidence of laryngeal squamous cell carcinoma (LSCC) is gradually increasing. 1,2 LSCC has a negative impact on patients' quality of life because it impairs their ability to breathe, swallow, and speak. 3 Despite advances in comprehensive LSCC treatment, the 5year survival rate has not decreased significantly in decades.…”

Section: Introductionmentioning

confidence: 99%

miR-1207-5p suppresses laryngeal squamous cell carcinoma progression by downregulating SKA3 and inhibiting epithelial-mesenchymal transition

Wu¹,

Dai²,

Zhang³

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Laryngeal squamous cell carcinoma (LSCC) is the second most common head and neck cancer. Previously, we discovered that miR-1207-5p was downregulated in LSCC. In this study, the clinical significance, function, and mechanism of miR-1207-5p in LSCC were investigated. Downregulation of miR-1207-5p was found to be strongly linked to the malignant progression of LSCC. Functional studies revealed that miR-1207-5p upregulation suppressed LSCC cell proliferation, invasion, migration, and xenograft tumor growth. Bioinformatics analysis revealed that miR-1207-5p target genes were involved in cell cycle regulation, proliferation, adhesion, and the phosphatidylinositol 3kinase (PI3K)/Akt pathway. Mechanistic studies revealed that miR-1207-5p interacts directly with the 3 0 untranslated region of spindle and kinetochore associated complex subunit 3 (SKA3) and downregulates SKA3 expression. Furthermore, SKA3 was found to be overexpressed in LSCC, and its high expression was associated with tumor progression and a poor prognosis. Rescue experiments demonstrated that miR-1207-5p inhibited the malignant phenotypes of LSCC via SKA3. Furthermore, miR-1207-5p upregulation or knockdown of SKA3 inhibited the epithelial-mesenchymal transition (EMT). Collectively, miR-1207-5p inhibited LSCC malignant progression by downregulating SKA3 and preventing EMT. These findings provide new insights into the mechanism of LSCC progression, as well as new potential biomarkers and therapeutic targets for LSCC diagnosis and treatment.

show abstract

“…Meanwhile, the SLC22A23 gene was selected as a differentially expressed gene in a study aiming to identify crucial genes involved in the pathogenesis of laryngeal squamous cell carcinoma [56]. A similar conclusion was also confirmed in another research reporting that the expression of SLC22A23 is associated with laryngeal cancer [57], suggesting that SLC22A23 may be involved in the development of laryngocarcinoma.…”

Section: B Analysis Of the Top Features Identified By The Mcfs Methodsmentioning

confidence: 69%

Screening Dys-Methylation Genes and Rules for Cancer Diagnosis by Using the Pan-Cancer Study

et al. 2020

View full text Add to dashboard Cite

Although cancer has long been a major public health problem worldwide, conquering cancer still remains unachievable due to its complexity and diversity. With the development of high-throughput sequencing technologies, the combination of conventional clinical symptoms and new genetic events is becoming effective and has been approved for precise prediction and innovative diagnostic strategies. Epigenetic modification (e.g., DNA methylation) is an important mechanism of transcriptional control in normal or disease functions. Depending on the unique methylation profiles, an important possibility raised is that the characteristic of dys-methylation could provide a new molecular marker system for the identification of the major forms of tumors. In this study, we attempted to distinguish different tumor types. On the basis of DNA methylation data from PanCanAtlas in The Cancer Genome Atlas, we applied mRMR and MCFS methods together to identify the decision rules for distinguishing 33 different tumor types and ranked the features that characterized methylation level. This study highlights the considerable application potential of methylation features in cancer diagnosis and provides insight into novel therapeutic targets. INDEX TERMS Methylation, rule, cancer diagnosis, pan-cancer.

show abstract

Investigation of the SLC22A23 gene in laryngeal squamous cell carcinoma

Cited by 13 publications

References 35 publications

Systemic characterization of the SLC family genes reveals SLC26A6 as a novel oncogene in hepatocellular carcinoma

Systemic characterization of the SLC family genes reveals SLC26A6 as a novel oncogene in hepatocellular carcinoma

miR-1207-5p suppresses laryngeal squamous cell carcinoma progression by downregulating SKA3 and inhibiting epithelial-mesenchymal transition

Screening Dys-Methylation Genes and Rules for Cancer Diagnosis by Using the Pan-Cancer Study

Contact Info

Product

Resources

About